Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 6, 2009, Pages 1201-1210

  Israyelyan, Anna ^a   Shannon, Edward John ^a,b   Baghian, Abolghasem ^a   Kearney, Michael T ^a   Kousoulas, Konstantin G ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

Breast cancer model; Constructed herpes virus type 1; Thalidomide; Virotherapy

Indexed keywords

ONCDSYN; ONCOLYTIC HERPES VIRUS; ONCOLYTIC HERPES VIRUS 1; THALIDOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; LUNG METASTASIS; LYMPH NODE METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HERPESVIRUS 1, HUMAN; HUMANS; INTERLEUKIN-2; INTERLEUKIN-5; LUNG NEOPLASMS; LYMPHOCYTES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; ONCOLYTIC VIROTHERAPY; SPLEEN; THALIDOMIDE; TREATMENT OUTCOME;

EID: 69049091862     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0987-8     Document Type: Article

References (50)

1. SJ Advani SM Chung SY Yan GY Gillespie JM Markert RJ Whitley B Roizman RR Weichselbaum 1999 Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors Cancer Res 59 2055 2058
2. RJ Amato M Morgan A Rawat 2006 Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma Cancer 106 1498 1506
3. V Apostolopoulos IF McKenzie C Lees KI Matthaei IG Young 2000 A role for IL-5 in the induction of cytotoxic T lymphocytes in vivo Eur J Immunol 30 1733 1739
4. O Arrieta P Guevara J Tamariz D Rembao E Rivera J Sotelo 2002 Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma Int J Exp Pathol 83 99 104
5. CJ Aslakson FR Miller 1992 Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor Cancer Res 52 1399 1405
6. AV Belo MA Ferreira AA Bosco RD Machado SP Andrade 2001 Differential effects of thalidomide on angiogenesis and tumor growth in mice Inflammation 25 91 96
7. Cadoz M, Seigneurin JM, Mallaret MR, Baccard C, Morand P (1992) Phase I trial of R7020: a live attenuated recombinant herpes simplex virus (HSV) candidate vaccine. Program and Abstracts of the 32nd interscience conference on antimicrobial agents and chemotherapy. American Society of Microbiology, Washington, D.C.
8. Z Cao WR Joseph WL Browne KG Mountjoy BD Palmer BC Baguley LM Ching 1999 Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5, 6-dimethylxanthenone-4- acetic acid Br J Cancer 80 716 723
9. LM Ching WL Browne R Tchernegovski T Gregory BC Baguley BD Palmer 1998 Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5, 6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity Br J Cancer 78 336 343
10. LM Ching ZF Xu BH Gummer BD Palmer WR Joseph BC Baguley 1995 Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5, 6-dimethylxanthenone-4-acetic acid Br J Cancer 72 339 343
11. F Chung J Liu LM Ching BC Baguley 2008 Consequences of increased vascular permeability induced by treatment of mice with 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide Cancer Chemother Pharmacol 61 497 502
12. PJ Cozzi PB Burke A Bhargav WD Heston B Huryk PT Scardino Y Fong 2002 Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses Prostate 53 95 100
13. PJ Cozzi S Malhotra P McAuliffe DA Kooby HJ Federoff B Huryk P Johnson PT Scardino WD Heston Y Fong 2001 Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model FASEB J 15 1306 1308
14. LS Downs Jr LM Rogers Y Yokoyama S Ramakrishnan 2005 Thalidomide and angiostatin inhibit tumor growth in a murine xenograft model of human cervical cancer Gynecol Oncol 98 203 210
15. WD Figg H Li T Sissung A Retter S Wu JL Gulley P Arlen JJ Wright H Parnes K Fedenko L Latham SM Steinberg E Jones C Chen W Dahut 2007 Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer BJU Int 99 1047 1055
16. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186
17. YX Fu G Watson JJ Jimenez Y Wang DM Lopez 1990 Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor Cancer Res 50 227 234
18. AM Gaya GJ Rustin 2005 Vascular disrupting agents: a new class of drug in cancer therapy Clin Oncol (R Coll Radiol) 17 277 290
19. A Gutermann E Mayer K Von Dehn-Rothfelser C Breidenstein M Weber M Muench D Gungor J Suehnel U Moebius M Lechmann 2006 Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells Hum Gene Ther 17 1241 1253
20. M Gutman A Szold A Ravid T Lazauskas O Merimsky JM Klausner 1996 Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo Anticancer Res 16 3673 3677
21. PA Haslett WA Hanekom G Muller G Kaplan 2003 Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro J Infect Dis 187 946 955
22. K Hellmann 2001 Angiogenesis: tumour size is no guide to malignancy Lancet Oncol 2 259 260
23. K Hubel DC Dale WC Liles 2002 Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma J Infect Dis 185 1490 1501
24. A Israyelyan VN Chouljenko A Baghian AT David MT Kearney KG Kousoulas 2008 Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice Virol J 5 68
25. AH Israyelyan JM Melancon LG Lomax I Sehgal C Leuschner MT Kearney VN Chouljenko A Baghian KG Kousoulas 2007 Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells Hum Gene Ther 18 457 473
26. N Kemeny K Brown A Covey T Kim A Bhargava L Brody B Guilfoyle NP Haag M Karrasch B Glasschroeder A Knoll G Getrajdman KJ Kowal WR Jarnagin Y Fong 2006 Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver Hum Gene Ther 17 1214 1224
27. AW Le Serve K Hellmann 1972 Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action Br Med J 1 597 601
28. H Li V Raia F Bertolini DK Price WD Figg 2007 Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model BJU Int 101 884 888
29. H Malonne I Langer R Kiss G Atassi 1999 Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors Clin Exp Metastasis 17 1 14
30. PF McAuliffe WR Jarnagin P Johnson KA Delman H Federoff Y Fong 2000 Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses J Gastrointest Surg 4 580 588
31. B Meignier R Longnecker B Roizman 1988 In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents J Infect Dis 158 602 614
32. B Meignier B Martin RJ Whitley B Roizman 1990 In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus) J Infect Dis 162 313 321
33. AI Minchinton KH Fryer KR Wendt KA Clow MM Hayes 1996 The effect of thalidomide on experimental tumors and metastases Anticancer Drugs 7 339 343
34. M Nakamori X Fu R Rousseau SY Chen X Zhang 2004 Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity Mol Ther 9 658 665
35. T Olencki S Malhi T Mekhail R Dreicer P Elson L Wood RM Bukowski 2006 Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma Invest New Drugs 24 321 326
36. BA Pulaski S Ostrand-Rosenberg 1998 Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines Cancer Res 58 1486 1493
37. R Rabinowitz G Katz M Rosner S Pri-Chen A Spierer 2008 The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity Graefes Arch Clin Exp Ophthalmol 246 843 848
38. JM Ruddy SK Majumdar 2002 Antitumorigenic evaluation of thalidomide alone and in combination with cisplatin in DBA2/J mice J Biomed Biotechnol 2 7 13
39. EJ Shannon RO Miranda MJ Morales RC Hastings 1981 Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy Scand J Immunol 13 553 562
40. E Shannon R Novek F Sandoval B Kamath 2008 Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide Immunopharmacol Immunotoxicol 30 447 457
41. EJ Shannon F Sandoval 1996 Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells Immunopharmacol Immunotoxicol 18 59 72
42. EJ Shannon F Sandoval 2008 Thalidomide and Thalidomide transformed by pH-dependent hydrolysis or by liver enzyme treatment does not impede the proliferation of endothelial cells Immunopharmacol Immunotoxicol 30 307 316
43. EJ Shannon FG Sandoval 2002 Thalidomide can costimulate or suppress CD4+ cells' ability to incorporate [H3]-thymidine-dependence on the primary stimulant Int Immunopharmacol 2 1143 1153
44. S Singhal J Mehta 2001 Thalidomide in cancer: potential uses and limitations BioDrugs 15 163 172
45. M Solti D Berd MJ Mastrangelo T Sato 2007 A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment Melanoma Res 17 225 231
46. Suckow MA, Danneman P, Brayton C (2001) The laboratory mouse. CRC Press, Notre Dame
47. K Takatsu Y Kikuchi T Takahashi T Honjo M Matsumoto N Harada N Yamaguchi A Tominaga 1987 Interleukin 5, a T-cell-derived B-cell differentiation factor also induces cytotoxic T lymphocytes Proc Natl Acad Sci USA 84 4234 4238
48. D Tweedie K Sambamurti NH Greig 2007 TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets Curr Alzheimer Res 4 378 385
49. Y Yamaguchi T Suda H Shiozaki Y Miura Y Hitoshi A Tominaga K Takatsu T Kasahara 1990 Role of IL-5 in IL-2-induced eosinophilia. In vivo and in vitro expression of IL-5 mRNA by IL-2 J Immunol 145 873 877
50. ZL Zhang ZS Liu Q Sun 2005 Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice Chin Med J (Engl) 118 1688 1694